Kenneth Thummel

Kenneth Thummel


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RTRakshit Sanjay Tanna
Rakshit Sanjay Tanna
JNJames Nguyen
James Nguyen
DHDeena L. Hadi
Deena L. Hadi
PMPreston Manwill
Preston Manwill
LFLaura Flores-Bocanegra
Laura Flores-Bocanegra
MPMary Paine
Mary Paine
Increasing use of the botanical kratom to self-manage opioid withdrawal and pain has led to increased kratom-linked overdose deaths. Despite these serious safety concerns, rigorous fundamental pharmacokinetic knowledge of kratom in humans remains lacking. We assessed the pharmacokinetics of a single low dose (2 g) of a well-characterized kratom product administered orally to six healthy participants. Median concentration-time profiles for the kratom alkaloids examined were best described by a two-compartment model with central elimination. Pronounced pharmacokinetic differences between alkaloids with the 3S configuration (mitragynine, speciogynine, paynantheine) and alkaloids with the 3R configuration (mitraciliatine, speciociliatine, isopaynantheine) were attributed to differences in apparent intercompartmental distribution clearance, volumes of distribution, and clearance. Based on noncompartmental analysis of individual concentration-time profiles, the 3S alkaloids exhibited a shorter median time to maximum concentration (1–2 vs. 2.5–4.5 h), lower area under the plasma concentration-time curve (430–490 vs. 794–5120 nM × h), longer terminal half-life (24–45 vs. ~12–18 h), and higher apparent volume of distribution during the terminal phase (960–12,700 vs. ~46–130 L) compared to the 3R alkaloids. Follow-up mechanistic in vitro studies suggested differential hepatic/intestinal metabolism, plasma protein binding, blood-to-plasma partitioning, and/or distribution coefficients may explain the pharmacokinetic differences between the two alkaloid types. This first comprehensive pharmacokinetic characterization of kratom alkaloids in humans provides the foundation for further research to establish safety and effectiveness of this emerging botanical product.

1 April 2018 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
TWTimothy Wong
Timothy Wong
ZWZhican Wang
Zhican Wang
BCBrian D. Chapron
Brian D. Chapron
MSMizuki Suzuki
Mizuki Suzuki
KCKatrina G. Claw
Katrina G. Claw
KTKenneth Thummel
Kenneth Thummel
Metabolism of 25-hydroxyvitamin D3 (25OHD3) plays a central role in regulating the biological effects of vitamin D in the body. Although cytochrome P450-dependent hydroxylation of 25OHD3 has been extensively investigated, limited information is available on the conjugation of 25OHD3. In the present study, we report that 25OHD3 is selectively conjugated to 25OHD3-3-O-sulfate by human sulfotransferase 2A1 (SULT2A1) and that the liver is a primary site of metabolite formation. At a low (50 nM) concentration of 25OHD3, 25OHD3-3-O-sulfate was the most abundant metabolite, with an intrinsic clearance approximately 8-fold higher than the next most efficient metabolic route. In addition, 25OHD3 sulfonation was not inducible by the potent hPXR agonist, rifampicin. The 25OHD3 sulfonation rates in a bank of 258 different human liver cytosols were highly variable, but correlated with the rates of dehydroepiandrosterone sulfonation. Further analysis revealed a significant association between a common SNV within intron-1 of SULT2A1 (rs296361; MAF = 15% in Whites) and liver cytosolic SULT2A1 content as well as 25OHD3-3-O-sulfate formation rate, suggesting that variation in the SULT2A1 gene contributes importantly to inter-individual differences in vitamin D homeostasis. Finally, 25OHD3-3-O-sulfate exhibited high affinity for the vitamin D binding protein and was detectable in human plasma and bile, but not in urine samples. Thus, circulating concentrations of 25OHD3-3-O-sulfate appear to be protected from rapid renal elimination, raising the possibility that the sulfate metabolite may serve as a reservoir of 25OHD3 in vivo, and contribute indirectly to the biological effects of vitamin D.

Verified
Journal Article
Open access
PDF file
LHLindsay Henderson
Lindsay Henderson
KCKatrina G. Claw
Katrina G. Claw
EWErica Woodahl
Erica Woodahl
RRRenee F. Robinson
Renee F. Robinson
BBBert B. Boyer
Bert B. Boyer
KTKenneth Thummel
Kenneth Thummel
Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, Métis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome P450 genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy.

1 December 2014 in Biochemical Pharmacology
Verified
Journal Article
Closed access
DSDiana L. Shuster
Diana L. Shuster
LRLinda J. Risler
Linda J. Risler
BPBhagwat Prasad
Bhagwat Prasad
JCJustina C. Calamia
Justina C. Calamia
JVJenna L. Voellinger
Jenna L. Voellinger
Qingcheng MaoQingcheng Mao
Qingcheng Mao

31 August 2021 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
CAChristopher M. Arian
Christopher M. Arian
TITomoki Imaoka
Tomoki Imaoka
JYJade Yang
Jade Yang
EKEdward J. Kelly
Edward J. Kelly
KTKenneth Thummel
Kenneth Thummel

1 March 2013 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
PBPaul E. Baker
Paul E. Baker
TCToby B. Cole
Toby B. Cole
MCMegan Cartwright
Megan Cartwright
SSStephanie M. Suzuki
Stephanie M. Suzuki
KTKenneth Thummel
Kenneth Thummel
CFClement E Furlong
Clement E Furlong